Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sabirnetug + rHuPH20
- Development stage
- Phase 1
- Lead developer
- Acumen Pharmaceuticals
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Sabirnetug + rHuPH20 is a combination drug product comprising sabirnetug (also known as ACU193), a humanized monoclonal antibody targeting amyloid-β oligomers, and rHuPH20 (recombinant human hyaluronidase PH20), an enzyme enabling large-volume subcutaneous drug administration. Sabirnetug selectively binds to soluble amyloid-β oligomers believed to drive synaptic dysfunction and neurodegeneration in Alzheimer’s disease, while rHuPH20 facilitates enhanced absorption and dispersion of the monoclonal antibody when delivered subcutaneously. This combination is developed primarily to provide subcutaneous administration as an alternative to intravenous infusion for patients with Alzheimer's disease, potentially improving convenience, accessibility, and adherence to therapy[3][5][1].
- Other names
- sabirnetug + ENHANZEsabirnetug + recombinant human hyaluronidase PH20
02
Targets
Aβ (Amyloid-beta peptides and aggregates)
Beyond the preview
Go deeper on sabirnetug + rHuPH20.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sabirnetug + rHuPH20.